Drug Profile
Research programme: anti-infective and anti-inflammatory therapeutics - Aeolus Pharmaceuticals
Alternative Names: AEOL 20415Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator National Jewish Medical and Research Center
- Developer Aeolus Pharmaceuticals Inc
- Class
- Mechanism of Action Immunostimulants; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Pseudomonal infections; Viral infections
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Pseudomonal infections in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Viral infections in USA (unspecified route)